| NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives AD Zelenetz, I Ahmed, EL Braud, JD Cross, N Davenport-Ennis, ... Journal of the National Comprehensive Cancer Network 9 (Suppl_4), S-1-S-22, 2011 | 194 | 2011 |
| Zoledronic acid: a new parenteral bisphosphonate EC Li, LE Davis Clinical therapeutics 25 (11), 2669-2708, 2003 | 194 | 2003 |
| National trends in prescription drug expenditures and projections for 2016 GT Schumock, EC Li, KJ Suda, MD Wiest, JA Stubbings, LM Matusiak, ... American Journal of Health-System Pharmacy 73 (14), 1058-1075, 2016 | 146 | 2016 |
| National trends in prescription drug expenditures and projections for 2016 VLC Schumock GT, Li EC, Suda KJ, Wiest MD, Stubbings J, Matusiak LM, Hunkler RJ Am J Health Syst Pharm 73 (14), 1058-75, 2016 | 84 | 2016 |
| Drug‐induced QT‐interval prolongation: considerations for clinicians EC Li, JS Esterly, S Pohl, SD Scott, BF McBride Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30 (7 …, 2010 | 84 | 2010 |
| National trends in prescription drug expenditures and projections for 2014 GT Schumock, EC Li, KJ Suda, LM Matusiak, RJ Hunkler, LC Vermeulen, ... American Journal of Health-System Pharmacy 71 (6), 482-499, 2014 | 82 | 2014 |
| Projecting future drug expenditures—2012 JM Hoffman, E Li, F Doloresco, L Matusiak, RJ Hunkler, ND Shah, ... American Journal of Health-System Pharmacy 69 (5), 405-421, 2012 | 78 | 2012 |
| NCCN task force report: specialty pharmacy RN Schwartz, KJ Eng, DA Frieze, TK Gosselin, N Griffith, AH Seung, ... Journal of the National Comprehensive Cancer Network 8 (Suppl_4), S-1-S-12, 2010 | 60 | 2010 |
| National trends in prescription drug expenditures and projections for 2015 GT Schumock, EC Li, KJ Suda, MD Wiest, J Stubbings, LM Matusiak, ... American Journal of Health-System Pharmacy 72 (9), 717-736, 2015 | 54 | 2015 |
| Development of biosimilars in an era of oncologic drug shortages E Li, J Subramanian, S Anderson, D Thomas, J McKinley, IA Jacobs Drug design, development and therapy, 3247-3255, 2015 | 49 | 2015 |
| Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database J Malon, P Shah, WY Koh, G Cattabriga, E Li, L Cao BMC Public Health 18, 1-12, 2018 | 47 | 2018 |
| New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies E Li, JA Trovato American Journal of Health-System Pharmacy 69 (12), 1031-1037, 2012 | 46 | 2012 |
| National trends in prescription drug expenditures and projections for 2018 GT Schumock, JA Stubbings, MD Wiest, EC Li, KJ Suda, LM Matusiak, ... The Bulletin of the American Society of Hospital Pharmacists 75 (14), 1023-1038, 2018 | 38 | 2018 |
| Considerations in the early development of biosimilar products EC Li, R Abbas, IA Jacobs, D Yin Drug Discovery Today 20, 1-9, 2015 | 36 | 2015 |
| Projecting future drug expenditures in US nonfederal hospitals and clinics—2013 JM Hoffman, E Li, F Doloresco, L Matusiak, RJ Hunkler, ND Shah, ... American journal of health-system pharmacy 70 (6), 525-539, 2013 | 33 | 2013 |
| Pharmacist Substitution of Biological Products: Issues and Considerations. E Li, S Ramanan, L Green J Manag Care Spec Pharm 21 (7), 532-9, 2015 | 30 | 2015 |
| ASHP Foundation pharmacy forecast 2017: strategic planning advice for pharmacy departments in hospitals and health systems WA Zellmer, SJ Knoer, PK Phelps, KC Marvin, A Pulvermacher, ... American Journal of Health-System Pharmacy 74 (2), 27-53, 2017 | 21 | 2017 |
| Spending on antineoplastic agents in the United States, 2011 to 2016 SJ Hong, EC Li, LM Matusiak, GT Schumock Journal of Oncology Practice 14 (11), e683-e691, 2018 | 20 | 2018 |
| NCCN oncology risk evaluation and mitigation strategies white paper: recommendations for stakeholders PE Johnson, G Dahlman, K Eng, R Garg, S Gottlieb, JM Hoffman, ... Journal of the National Comprehensive Cancer Network 8 (Suppl_7), S-7-S-27, 2010 | 20 | 2010 |
| Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: a cost-effectiveness analysis E Li, DJ Mezzio, D Campbell, K Campbell, GH Lyman JCO Oncology Practice 17 (8), e1235-e1245, 2021 | 19 | 2021 |
